Indivumed is a physician-led, integrated global oncology company for personalized medicine with the world’s premier high-content tumor database and highest-quality biobank. Our range of diverse services and products is tailored to customers’ needs in translational and clinical research and molecular diagnostics.
Our reputation for excellence is built on our standard operating procedures for biospecimen collection: “Indivumed Standard”.
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
RaDaR™ is a multi-tumor personalized liquid biopsy assay for the detection of residual disease and early detection of relapse. RaDaR is based on the InVision® tagged-amplicon sequencing method. The method incorporates amplification and deep sequencing of targeted genomic regions and includes built-in controls and error-correction for highly sensitive and specific variant detection. RaDaR is being used in clinical trial applications where it has potential to speed clinical trials by focusing recruitment and by giving earlier visibility of drug efficacy.